Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lttl vs YOURx Health

Lttl
Graded #205

Lower grade

vs+3.700000000000003
YOURx Health
Graded #118

Higher grade

The verdict

YOURx Health takes it — 69.8/100 to 66.1/100.

YOURx Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YOURx Health (yourxhealth.com) is a compounded GLP-1 telehealth platform powered by the MD Integrations provider network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueYOURx Health +10
56
66
Dose & formulationLttl +21
96
75
Clinical oversightYOURx Health +4
76
80
Labs & monitoringYOURx Health +23
52
75
FulfillmentLttl +14
69
55
Contract termsYOURx Health +35
20
55
Lttl · left barYOURx Health · right bar

The numbers

MetricLttlYOURx Health
WeighScore66.1/10069.8/100
GradeCC
Scorecard rank#205#118
Semaglutide$199/mo (all doses, compounded)$179/mo (compounded)
Tirzepatide$279/mo (all doses, compounded)$199/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Lttl

Graded #205 · C

Strengths

  • Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
  • Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
  • States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
  • Oral ODT semaglutide offered for members who want to avoid injections

Where it loses points

  • Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
  • The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
  • No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
  • Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
  • Medications cannot be returned or refunded once they ship from the pharmacy
YOURx Health

Graded #118 · C

Strengths

  • Lab monitoring included (per the home page) — most peer platforms gate labs as add-ons or skip them entirely
  • Physician video consultation with 'board-certified provider' disclosed
  • MD Integrations network is a recognized white-label clinical platform
  • Transparent published pricing: semaglutide injection $179/mo, tirzepatide injection $199/mo, oral RDT tablets $159-$179/mo

Where it loses points

  • Parent company / legal entity name NOT publicly disclosed — material YMYL transparency gap
  • NO LegitScript / NABP / PCAB / BBB seal displayed — material trust-signal gap vs peer platforms
  • Per-state availability shown as 'Coverage 0 States' (placeholder metric) — appears the home page is incomplete or the platform is pre-launch
  • Pharmacy partners NOT publicly named
  • Confidence LOW until the platform exposes more public information

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard